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Abstract
Background: Gastroparesis (Gp) is a poorly understood chronic gastrointestinal medical condition for which patient
reported outcomes (PRO) are lacking. Previously developed symptoms scoring has been used for several decades.
Using symptoms scores as a basis for documentation, 12 years of support/focus group patient feedback from the
nearly 1000 attendees were integrated with medical care and recommendations for treatment were developed.
Early attenders of the support group were compared with non-attendees for illness acuity, disability, and duration
and number of office phone calls.
Methods: Patients cared for in an academic medical practice were assessed for patient-derived PRO symptoms,
coupled with standardized Health Related Quality of Life (HRQOL) measures. Based on factors identified by the
patients via support/focus groups, a diagnostic and prognostic tool was developed.
Results: The new tool utilized PRO symptoms and included provider assessments of medical illnesses as well as
resource utilization. This ‘post PRO’ tool has been applied in a variety of settings for patients with the symptoms
of Gp over the last two decades. The ‘pre-PRO’ factors from the support/focus groups were compared to the PRO
measures as well as the ‘post-PRO’ scale to assess their usefulness. Using methods that combine chart data,
including electronic medical records (EMR), with PRO symptoms may have design implications for PRO assessment.
The resultant scales, as part of a new tool, can allow for sharing of PRO derived scores in a chronic gastrointestinal
(GI), illness with different practitioners.
Conclusions: These newly-derived scales offer a potentially useful tool for clinical decision-making, tailoring
treatment to patient subgroups and engaging both patients and their families and caregivers in more active
partnerships with providers to improve health outcomes.
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Background
Gastroparesis (Gp) is a chronic disorder, which is classic-
ally defined as when the stomach takes too long to empty
its contents; many patients have Gp symptoms even with-
out measured delayed gastric emptying or gastroparesis-
like syndrome, otherwise known as unexplained nausea
and vomiting (UNAV) [1]. Together, these disorders can
be called the Gp Syndromes. Common symptoms include
chronic and/or recurrent vomiting, nausea, bloating/dis-
tension, loss of appetite/early satiety to meals and abdom-
inal pain. The most common known causal agent of Gp is
diabetes (Type I and Type II), accounting for 30 % of the
cases [2]. Diabetic (DM) Gp or DM Gastropathy, if non
delayed gastric emptying, is associated with high levels of
blood glucose that cause chemical changes in nerves and
blood vessels that supply oxygen and nutrients to nerves,
especially the vagus nerve. Gp can occur with autonomic
nervous system damage [3] as well as enteric nervous
system damage, as a result of surgery on the stomach, and
from viral infections. Roughly 70 % of people suffering
from Gp have idiopathic gastroparesis, meaning the cause
is unknown even after medical testing [4]. Complications
from Gp include chronic nausea, bloating, vomiting, loss
of appetite, weight loss and infection [3]. These complica-
tions can become so debilitating that many people suffe-
ring from Gp become bedridden and spend portions of
their lives in and out of hospitals, greatly reducing the
patients’ health related quality of life (HRQOL). Manage-
ment by a team of clinicians skilled in addressing psycho-
physiological needs of the patient, facilitating patient and
family education, and providing general support, can en-
hance coping and control, which positively impact quality
of life [3, 5].
Over the course of 25 years, two of the authors (TA and
TC) have worked with patients with symptoms of Gp.
Consequently, they pursued the development of tools for
patient experience reporting (which we term “pre-PRO or
pre-Patient Reported Outcomes”), as a means of docu-
menting the patient’s experience and making recommen-
dations for advocacy and improved treatment of Gp. Such
development of defined and reliable PROs for use in Gp
patients has been recommended by the US Center for
Drug Evaluation and Research (CDER) [6].
This paper describes findings from 12 years of conduc-
ting supportive therapy groups with persons experiencing
neuro-gastrointestinal disorders, particularly gastroparesis,
measurement of health related quality of life, and the de-
velopment of provider and patient rating tools (pre-PROs)
in this group over two decades. Essentially, our earliest
PRO tool development started in the 1980’s in our drug
studies of patients treated with pharmacologic agents such
as cisapride, with evaluation of nausea/vomiting parame-
ters based on the metrics of FDA approved studies at the
time [7]. These patient-reported outcome scales, which
included measures of nausea, vomiting, anorexia/early sati-
ety, bloating/distension and abdominal pain, on a 0–4 scale
with none to worse, were also evaluated by their frequency
and severity and can be summarized as a total symptom
score (or TSS) by adding the symptoms together. This FDA
derived PRO scale has been used by our patient population
for the last 30 years. Based on learning from patients, and
what the patients thought were their main concern from
patient support and focus groups, we created the ADAPS/
IDIOMS tools in 1995, which was used along with the PRO
measures including TSS (Additional file 1). Finally, we con-
ducted work further validating all these tools (patient symp-
toms by PRO/TSS with the tool of ADAPS/IDIOMS) and
with the SF-36 in the 2000s (Additional file 2). Figure 1
gives highlights of this process and the tool development.
Methods and approach
Health Related Quality of Life (HRQL), Patient Reported
Outcomes (PRO) with patient and provider rating tools
HRQL refers to either specific or global measures of
subjective well-being. Tools for HRQL assessment can
be useful in predicting outcomes, tailoring treatment and
encouraging patient self-management of disease [8]. In
addition to HRQL, patient-reported outcomes or PROs
have become increasingly common in use for clinical care
and tap similar domains as specific HRQL tools. PROs
have been defined as “any report of the status of a patient’s
health condition that comes directly from the patient,
without interpretation of the patient’s response by a clin-
ician or anyone else.”. These tools enable assessment of
patient–reported health status for physical, mental and so-
cial well–being, a variant of an HRQL measure. A wide
variety of patient-level instruments to measure PROs have
been used for clinical research purposes. Many of these
have been evaluated and cataloged within NIH’s Patient
Reported Outcomes Measurement Information System
(PROMIS). While PROMIS and other initiatives have vali-
dated patient-level outcome measures and instruments,
there are two major challenges to using them for purposes
of accountability and performance improvement:
1. They are not in widespread use in clinical practice.
2. Little is known about aggregating these patient-level
outcomes for measuring the performance of the
healthcare entity delivering care [9].
Early prototypes of PROs used by the authors, like patient
symptom ratings, coupled with our provider rating tools,
have aided in establishing a more holistic understanding of
gastroparesis patients’ sense of well-being and the inter-
ruption of that sense of well-being due to complications
related to gastroparesis. Particularly, our work has always
included patient ratings (pre-PROs), as well as provider
ratings. We contend that this mirror assessment offers a
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more comprehensive picture of the patient experience and
provider view and lends itself to promoting both informed
and activated patients and providers who feel more self-
efficacy: the patient-provider partnership now advocated by
the Institute for Healthcare Improvement and others [10].
Lastly, the development of defined and reliable PROs
for use in Gp patients has been recommended by the
CDER [6], who conclude that ideal PRO tools are lacking
currently:
“Because gastroparesis is a symptomatic condition, a
well-defined and reliable PRO instrument that measures
all the clinically important signs and symptoms of gastro-
paresis would be the ideal primary efficacy assessment tool
in clinical trials used to support labeling claims for the
treatment of gastroparesis. However, at the current time,
we know of no measure of clinically important gastropar-
esis signs and symptoms that would serve as the ideal pri-
mary efficacy assessment tool. Until an appropriate PRO
instrument for gastroparesis becomes available, sponsors
should consider the strategies discussed in the following
sections when designing gastroparesis clinical trials. Spon-
sors may wish to explore new PRO instruments or novel
diagnostic measures in early development, and potentially
correlate the results with dose-ranging trials.”
We believe that the rating tools developed and de-
scribed below constitute “new PRO instruments or novel
diagnostic measures in early development” suggested by
the CDER [6].
Early drug studies and Pre-PRO tools
From early 1983 to present, one of the authors (TA) has
served as a PI on studies exploring drugs and other treat-
ments for gastroparesis, starting with Cisapride investiga-
tions in the mid-1980s. Early studies had the patients rate
nausea and vomiting levels as part of structured clinical
trials, a precursor to the Total Symptom Score or TSS tool
described below [7, 11]. See Additional file 1 for an
example of the utilized PRO/TSS.
ADAPS/IDIOMS tools
Methodologies to determine the best patient care for
people suffering from gastroparesis continued to be deve-
loped and refined by the corresponding author and his
teams in the late 1980s through the 1990s. Along with the
PRO/TSS, early work with patient ratings included a Symp-
toms Interview based on the severity and frequency of
symptoms and the Short Form – 36 Version 1, a well-
validated and psychometrically sound Health Related
Fig. 1 Process Flow of Development of Patient and Provider Rating Tools
Cutts et al. BMC Gastroenterology  (2016) 16:107 Page 3 of 9
Quality of Life Measure. Two authors (TC and TA) then
developed a provider-rating tool which was initially called
A Diagnostic And Prognostic Score (or ADAPS) and later
called the Investigator Derived Independent Outcomes
Measure Score or IDIOMS. Essentially the ADAPS/ID-
IOMS tool was developed around 1995 to evaluate three
specific areas of patient experience, based on what patients
named as important to them: (1) what they wanted to be
addressed medically; (2) how sick they were with GI symp-
toms other medical problems, and; (3) what services they
needed, a gross healthcare utilization measure. These areas
correspond to healthcare utilization domains used as com-
ponents of the Diagnostic Related Groups (DRGs) that the
Center for Medicare & Medicaid Services (CMS) uses to
set reimbursement rates [12]. The GI specific provider
rating or IDIOMS was also incorporated to determine its
usefulness as a synergistic tool in cooperation with patient
reported symptoms.
In the ADAPS/IDIOMS tool (Additional file 1) each of
these three domains is assessed on a 1–5 scale and a total
summed score, ranging from 1 to 30. Patient symptom
ratings (termed total symptom scores or TSS), the IDIOMS
and its earlier versions (e.g., the ADAPS) continually have
been used by our GI motility team, in several locations,
since 1995.
Support group therapy/Focus groups
From April 1990 to April 2002, support group sessions
were held for GI motility disorder patients at University of
Tennessee Health Science Center. These sessions occurred
monthly (except for 4 months), then staggered to quarterly
for the last 2 years, for a total of about 120 sessions.
Although detailed demographic records were not kept, over
1000 non-unique persons attended these groups over the
12-year period; attendance ranged from 5 to 45 patients
plus additional GI academic and clinical staff per session.
The group was started in part because the behavioral
management strategies for GI symptoms used at that time
(mostly to cope with musculoskeletal pain) did very little to
aid GI motility disorder patients, and the team wished to
offer other self-management strategies to help patients
coping with these difficult illnesses. There were few medical
options for GI motility patients; gastric electrical stimula-
tion, now used in some drug refractory patients, was still
investigational. Comparisons between early support group
attendees and non-attendees, matched on illness acuity,
disability and duration, suggested that attendees required
fewer pain medication prescriptions, made fewer calls and
requests of their providers, and used fewer outpatient
healthcare resources, compared to non-attendees [8].
Support group format consisted of introductions (partici-
pants briefly telling their stories), followed by a professional
speaker, and a subsequent question and answer period.
Support group sessions lasted around 90 min, but often
participants stayed for over 120 min. Focus group topics
included pain management, partnering with your medical
team, nutritional issues, total parenteral nutrition (TPN),
family dynamics in chronic illness, navigating the insurance
system, physical activity to improve motility function, cop-
ing with cyclic vomiting syndrome for adults and children,
financial management when dealing with a chronic illness,
autonomic nervous system function impact on GI symp-
toms, diabetes and GI motility disorder symptoms, coping
with depression and anxiety, biofeedback for pain manage-
ment, anger management, GI stimulation (pacing), dealing
with social isolation secondary to nausea, vomiting, as well
as explosive diarrhea and bloating.
Many patients found an understanding venue in which
to share, often resulting in crying, anger or other strong
negative emotions, but patients also laughed together.
The group had many “inside” jokes and prided themselves
on being able to laugh about vomiting and other socially
unacceptable behaviors. Unilaterally, group members found
that the group helped instill hope, as well as bolster their
morale and courage in coping with Gp [8]. However, be-
cause the group was hospital-based and many of the more
severely ill patients attended (with IV poles and in hospital
gowns), some early outpatient attendees reported that see-
ing other patients with like illnesses who were so critically
ill could be demoralizing. Some outpatients reported in-
creased anxiety upon hearing about the rapid trajectory of
illness severity and impairment for their hospitalized peers.
Additionally, prior misdiagnoses and psychiatric overlay
often placed upon patients (especially in rural areas with
few specialists), generated many stories that shared how
these experiences contributed to their pain and suffering.
While all were allowed to share their stories and empathy
was offered, the group focused on how to partner with
healthcare professionals, versus feeling victimized by unin-
tended iatrogenic impact from the medical and insurance
systems.
The group also provided a forum for families and other
patients to honor and memorialize those who died, and
was a good venue for grief counseling for many families,
once the family was ready to share about their loss. Unfor-
tunately, many patients in our cohort (roughly 25 % from
the initial University of Tennessee patient group) died in
the course of those 12 years, with an 11.3 % mortality rate
reported for a cohort of 214 who were treated with gastric
electrical stimulation [13].
Additionally, the group often shared their complemen-
tary medicine modalities with one another and joked
about writing a “GI Motility Handbook of Home Reme-
dies.” Interesting home-based modalities included eating
Vietnamese soup and greasy Krystal burgers or having a
family member use a plunger to “suction” the patients’
back or side when bloating was painful, etc., all offering
some measure of relief for some patients. The group
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facilitator did not promote these measures as alternative
medicines or substitutes for allopathic medicine, and always
urged patients to consult with the GI motility team.
These support groups provided a good venue for buil-
ding team partnerships with families and patients to im-
prove treatment and communication, before patient and
family-centered care or activated patient concepts were
considered important or even named [5]. Anecdotal infor-
mation learned from patients about the experience of
living with these disorders, as well as the impact on family
life and coping were useful in creating/directing holistic
treatment plans. Sharing from patients in these support
groups helped the authors develop tools that combined
health related quality of life measures or “pre-PRO”
assessments, as ways to better capture and integrate the
patient experience into treatment.
Ethics, consent and permissions
All research and data analysis was approved by the Univer-
sity of Mississippi and University of Tennessee Institutional
Review Boards and by IRBs at subsequent gastrointestinal
(GI) team locations at the University of Mississippi and the
University of Louisville. A waiver of consent was obtained
from the authorizing IRB.
Results
Total symptom score or TSS
Our team initially reported that prospective ratings of
vomiting and baseline quality of life were good predictors
of all-cause mortality in Gp patients followed for several
years [14]. We then explored the association between base-
line patient-generated symptoms of nausea and vomiting
frequency and severity as a PRO tool with SF-36 scales in
patients with Gp and reported on the use of patient
nausea/vomiting ratings including the TSS as a PRO tool in
2009 [15]. Patient symptom ratings of frequency and seve-
rity of nausea, vomiting and epigastric pain were examined
at baseline in a large cohort of patients with Gp. The SF-36,
a well-standardized functional measure of subjective
well-being and HRQOL, has been shown to be useful in
demonstrating the impact of illness in various patients
with various GI disorders, particularly Gp. We compared
baseline SF-36 scores and nausea and vomiting ratings in
235 patients with gastroparesis, mean age 47 years; 79 %
female, 21 % male; 82 % Caucasian, 17 % African-Ameri-
can, 1 % other ethnicity. Etiology of Gp for those rated was
idiopathic (53 %), diabetic (29 %) and post-surgical (12 %).
Significant Pearson correlation coefficients were found be-
tween SF-36 Social Functioning and vomiting severity (r =
−.236, p = .0001). SF-36 Role Emotional correlated signifi-
cantly with epigastric pain severity (r = .194, p = .003).
Examining the same cohort of patients with Gp, we
reported more in-depth correlations on the association
between baseline patient-generated symptom logs with
SF-36 scales [16]. Symptom logs included the Total Symp-
tom Score (TSS), ratings made by patients, rating frequency
and severity of nausea, vomiting, bloating, early satiety,
epigastric pain and burn, postprandial fullness and cardiac
burn. Significant Pearson correlation coefficients, both posi-
tive and negative, were found between SF-36 Physical Func-
tioning score and bloating severity (r= −.202, p = .002) and
bloating frequency (r = −.188, p = 004) and epigastric pain
(r= −.180, p = .006). SF-36 Bodily Pain scores correlated
significantly with bloating severity (r = − .220, p = 001),
bloating frequency (r = − .186, p = .005), epigastric pain
severity (r = −.190, p = .006) and epigastric pain frequency
(r= −.196, p = .004) and epigastric burn frequency (r =
−.204, p = .003). SF-36 Social Functioning also correlated
strongly with epigastric pain frequency (r = −.188, p = .005)
and vomiting severity (r = −.236, p = .000). SF-36 Role
Emotional correlated significantly with bloating severity
(r = −.284, p = .000) and bloating frequency (r = −.225,
p = .001) and epigastric pain severity (r=. 194, p = .003).
Lastly, SF-36 mental health scores correlated significantly
with bloating severity (r = −.182, p = .005) (Figs. 2, 3 and 4).
PROs via our GI symptom ratings of vomiting frequency
and severity, as well as epigastric pain severity, demon-
strated strong associations with SF-36 measures of Social
and Emotional functioning level, in the baseline ratings of
this Gp cohort. In this sample, vomiting and pain have a
strong impact on patients’ subjective ratings of well-being.
PROs via our GI symptom ratings of bloating frequency
and severity, as well as epigastric burn and pain severity
and frequency, demonstrated strong associations in the
baseline ratings of this GP cohort as well. These findings
suggest that these GI symptom ratings possess some degree
of concurrent validity with sub-scales of the SF-36 and
could be used as PROs.
Validation of IDIOMS and TSS with HRQOL measures
Finally, we reported on the concurrent validity and use
of our PRO symptoms and, the Investigator-Derived
Independent Outcome Measures Scores (IDIOMS) in this
cohort of patients with Gp [17]. Early studies demon-
strated that the IDIOMS correlated highly with some
global measures of HRQOL measures, including the Sick-
ness Impact Profile and Psychological General Well-Being
Scale. When we compared baseline IDIOMS and SF-36
scores in 242 patients with Gp, significant Spearman
correlation coefficients were found between IDIOMS
intensity of service and SF-36 Bodily Pain (p = .002), Social
Functioning (p = .021) and Mental Health (p = .021).
These findings suggest that the IDIOMS does possess
concurrent validity with sub-scales of the SF-36, and
merits further investigation as such a tool to measure
treatment outcomes. Highlights of these findings are pre-
sented in Figs. 2, 3 and 4.
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The IDIOMS tool has been demonstrated to have high
inter-rater reliability (r = 0.96, p < 0.001) in a study of 134
Gp patients rated at multiple intervals by two independent
practitioners [18]. Convergent validity, or how well a meas-
ure correlates with standardized and psychometrically
proven HRQOL measures of the same domains, constructs
or areas, has also been demonstrated for the IDIOMS with
the Sickness Impact Profile (SIP) and the Psychological
General Well-being Scale (PGWB), as well as patient symp-
tom ratings, in earlier studies of intractable Gp patients,
some undergoing gastric electrical stimulation (GES).
Likewise, the IDIOMS tool has shown to have good
predictive validity, or clinical responsiveness, which is the
ability of an instrument to demonstrate a difference in
measurement that corresponds with symptom change from
baseline after treatment or in predicting outcome. Several
studies have demonstrated that the ADAPS/IDIOMS is
clinically responsive in short-term treatment of GES, in a
longer term follow-up of GES patients, and in patients
treated with both prokinetics and biofeedback [19]. A re-
cent study of 441 consecutive Gp patients showed that the
baseline IDIOMS score was a highly significant indicator of
Fig. 2 IDIOMS Tool and Correlations with SF-36 Measure in a Sample of Patients with the Symptoms of Gastroparesis
Fig. 3 Correlation of Patient PROs Reported as GI Total Symptom Scores with SF-36 Measures in a Sample of Patients with the Symptoms
of Gastroparesis
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death (p <0.001), as was the symptom rating of vomiting at
baseline (p = 0.0333) [10].
In a recent cohort of Gp patients, bloating and abdominal
pain were commonly reported as the initial onset symp-
toms perceived by Gp patients progressing with severity of
the disease to nausea and vomiting. PRO-reported bloating
and abdominal pain severity scores significantly correlated
with abnormal gastric motility measures indicative of a
progressive disease state [20]. In this cohort of gastroparesis
patients (with mean symptom duration just over 7 years),
we concluded that ADAPS/IDIOMS shows usefulness in
terms of serving as a brief and reliable PRO tool, mainly in
terms of prognosis. Given that it has now been shown to
have some convergent validity in terms of correlating with
specific subscales of the SIP, Psychological General
Well-Being Scale [17], and the SF-36 (particularly Role-
Emotional and Bodily Pain), we think that the IDIOMS is
promising as a PRO tool to supplement more invasive and
longer global measures of HRQOL.
Discussion
The use of patient-reported outcomes has become increas-
ingly important in all aspects of medical care. The FDA
recently reviewed the application of PRO measures related
to studies for patients with gastroparesis [6]. As pointed
out in this document, newer measures of patients’ symp-
toms, although widely studied, have not been shown to be
superior to the PRO/TSS measures used in this report.
Although not originally designed for use in patient-
centered disease-management efforts, our team believes
that incorporating the IDIOMS tool into clinical care
could be useful as a complementary healthcare utilization
measure. These sorts of tools, coupled with traditional
PRO measures including TSS, could be used in improving
patient symptoms and outcomes, particularly in a primary
care setting, and could potentially be used in other patient-
provider interactions, such as Gp self-management training
(e.g., similar to Stanford’s Chronic Care Management
community-based trainings). Additionally, as suggested
earlier, the IDIOMS tool offers a clinician-friendly measure
that could be used with a variety of chronic conditions,
beyond Gp, as a population health management tool [3].
Future comparative or concurrent validity studies with
the IDIOMS tool with more widely-used GCSI and
PAGI-QOL tools, could be useful in discerning exactly
what instruments are best suited for patient needs, PRO
protocol development and population health management.
For example, such an assessment tool package could shape
and form more tailored treatment for patients based on
etiology and severity of motility disorder conditions, as well
Fig. 4 Correlations of IDIOMS Tool with patient PRO Measures Reported as GI Total Symptom Scores in Patients with the Symptoms
of Gastroparesis
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as other chronic co-morbid conditions. Additional work
with the IDIOMS tool can include further use for stratifi-
cation of patient sub-types, for both clinical and clinical
research applications, and the correlation of IDIOMS with
subsequent health care costs when following patients
longitudinally.
Conclusions and recommendations
One of the difficulties in using global HRQOL tools is that
they fail to comprehensively reflect the holistic experience
of gastroparesis patients having a traumatic illness that
greatly impairs quality of life over several years [21].
Generic HRQOL measures do not adequately reflect se-
verity of illness, extent of other organ involvement (which
is often extensive in patients with Gp), or utilization of
healthcare resources. Additionally, recent European stu-
dies suggest that only 40 % of patients actually complete
PROs as requested by PCPs or other providers [22]. Our
IDIOMS tool may fill a significant gap in reflecting the full
clinical experience of the illness, which is a primary goal
of patient-reported outcomes. Further study of our tool is
needed with more patients, at earlier stages of their Gp
course, to validate and refine its clinical utility and effect-
iveness across the spectrum, from those with early diagno-
ses and more minimal symptoms to those with intractable
symptoms. It is likely that early detection could be im-
proved by educating and targeting primary care providers
who often are the first practitioners to encounter patients
manifesting the early symptoms of Gp.
Patient reports supported the clinical utility of the ID-
IOMS and PRO/TSS tools from an HRQL standpoint.
In anecdotal reports gleaned from our support groups,
patients reported that learning behavioral strategies was
helpful in improving HRQOL by enhancing overall coping
skills and decreasing their sense of hopelessness/helpless-
ness. Such strategies included limiting known nutritional
substances that exacerbate bloating, pain coping or energy
pacing techniques and managing anxiety at the beginning
of a vomiting cycle.
In summary, the IDIOMS and PRO/TSS tools offer both
a brief clinician-friendly instrument that has shown good
inter-rater reliability and concurrent validity with a series of
different global standardized measure subscales of HRQOL
(e.g., SIP, PGWB, SF-36), as well as a patient rating that has
been used extensively. The SF-36 Role-Emotional and
Bodily Pain scales are related to the IDIOMS Intensity of
Service and Other Organ Involvement scales. The IDIOMS
Intensity of Service scale is also correlated with bloating
severity and frequency [17]. We also suspect that the ID-
IOMS, which is based on patient self-reports, may be a use-
ful complement to other PRO measures in any chronic GI
syndrome (e.g., IBS or functional dyspepsia), to reflect the
holistic experience of these illnesses over time. Additionally,
incorporating the IDIOMS and TSS tools as patient-related
outcome measures can help providers understand the
phenomenological experience of the illness itself, a most
important variable in promoting patient self-management
efforts in these chronic and often debilitating illnesses [21].
As such, we believe these tools deserve further study with
Gp cohorts, to continue to refine their usefulness in early
assessment and possible tailoring of interventions for diffe-
rent stages of the disease process in Gp and other chronic
GI syndromes.
Lastly, The National Quality Forum, in its December
2012 report, advocated for use of PROs as part of a popula-
tion health management strategy [3]. We propose that our
IDIOMS and PRO/TSS tools could be part of an ensemble
of measures that could be used, not only for chronic GI
illnesses like gastroparesis, but also for a host of other
chronic conditions, such as diabetes, obesity, cardiovascular
disease and others.
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